The GLP-1 Gold Rush and the Mistake Many Practices Are Making

Founder Perspective

A founder’s perspective after speaking with thousands of physicians about what creates durable, long-term practices.

GLP-1 medications have created one of the largest shifts in metabolic medicine in decades.

Demand is extraordinary.

Patients are asking for these medications by name. Practices are seeing rapid growth. New clinics are launching every week. For many providers, GLP-1 has been a welcome breakthrough — both clinically and economically.

But there is a pattern emerging that feels very familiar. And history suggests we should pay attention to it.

We’ve Seen This Pattern Before

Over the past several decades, we’ve seen multiple waves of weight-loss solutions capture public attention:

• SlimFast
• infomercial weight-loss pills
• detox programs
• shake diets
• prescription stimulant clinics
• keto programs

Each wave promised a simpler answer to a complex problem.

Patients rushed in. Results were often dramatic at first. And then the cycle repeated.

GLP-1 medications are different in one critical way:

They are legitimate medical breakthroughs. They work.

But the consumer psychology surrounding them looks very familiar. In many ways, we have replaced the infomercial with a prescription pad.

The Misunderstanding Fueling the Surge

A BodySite physician who operates five clinics serving more than 10,000 patients recently shared an observation that stuck with me:

“The reason GLP-1 is exploding is because most consumers don’t really understand how it works.”

Many patients believe the medication directly causes weight loss — almost like flipping a metabolic switch.

But GLP-1 medications primarily work by influencing appetite regulation:

• reducing hunger signals
• increasing satiety
• slowing gastric emptying
• helping patients feel full sooner

In other words, they help patients sustain the behavioral changes required for weight loss.

That distinction matters.

Because when patients believe the medication itself is the solution, they often assume the work has been removed from the equation. But long-term outcomes still depend on behavior, environment, education, structure, and support. The medication changes the playing field — it doesn’t eliminate the game.

The Business Risk for Practices

When patients search primarily for the medication itself, something important happens:

The practice becomes associated with the prescription — not the care model, not the long-term outcomes, not the patient relationship.

Just the medication.

And once the medication becomes the primary identity of the practice, competition changes.

Practices are no longer competing only with other local physicians. They are competing with national brands, venture-backed telehealth companies, and large consumer health platforms built to win on:

• price
• convenience
• marketing scale
• consumer reach

Most local practices will not win by trying to out-advertise or out-scale them. And in the long run, they probably shouldn’t try.

What Happens When the First Wave Evolves

Over the next several years, many patients will enter a second phase of their journey:

• plateaus
• weight stabilization
• medication discontinuation
• desire for maintenance strategies
• questions about long-term health
• interest in sustainability

When that happens, they will begin looking for something more comprehensive.

Not just a prescription.

A strategy. A relationship. A long-term plan.

The question becomes: will they come back to the same practice? Or will they search for a provider who offers more complete support?

The Practices That Will Win the Next Decade

The practices most likely to thrive will not be those built solely around prescribing GLP-1.

They will be practices that use GLP-1 as one component of a broader metabolic care model.

They focus on:

• education
• behavior change
• longitudinal care
• nutrition guidance
• accountability structures
• patient engagement
• habit formation

GLP-1 becomes an entry point into a longer patient journey — not the entire journey itself.

Aligning Patient Outcomes with Business Outcomes

Interestingly, the strategy that produces the best patient outcomes also produces the most durable practices.

Practices focused primarily on prescriptions often experience:

• higher churn
• transactional relationships
• greater price sensitivity
• shorter patient lifecycles

Practices focused on long-term outcomes tend to build:

• stronger retention
• greater trust
• more referrals
• longer patient relationships
• more professional satisfaction

Doing the right thing clinically often turns out to be the most stable business strategy.

A Founder’s Perspective

I’m not a physician.

But over the past decade, I’ve had the opportunity to work closely with thousands of providers and observe patterns across many different practice models.

One pattern repeats consistently:

Short-term solutions tend to create short-term practices.

Long-term patient relationships create durable practices.

GLP-1 medications are one of the most powerful tools we’ve ever had for metabolic health.

But they are not the business model.

They are one component of the model.

Closing Thought

GLP-1 is a remarkable advancement in medicine.

But medications alone rarely create transformation.

Transformation usually happens when treatment is combined with education, structure, and sustained support.

The practices that understand this now are likely to become the most trusted metabolic health providers of the next decade.